Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
OptiMATe trial (MATRix): what clinicians have said so far
OptiMATe: De-escalated Induction Treatment in Primary CNS Lymphoma
- NCT04931368 ↗
- Active, not recruiting
- Klinikum Stuttgart
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on OptiMATe (MATRix in newly diagnosed primary CNS lymphoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on OptiMATe so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 7 posts on X, typically up to 31 once built | |
| 1 podcast episode, typically up to 4 once built |
The trial
ClinicalTrials.gov- Official title
- Optimizing MATRix as Remission Induction in PCNSL: De-escalated Induction Treatment in Newly Diagnosed Primary CNS Lymphoma - a Randomized Phase III Trial
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Primary Central Nervous System Lymphoma
- Interventions
- Experimental Treatment: one course Rituximab/HD-Methotrexate, two courses of MATRix; Control intervention: four courses of MATRix
- Arms
- Control treatment (Arm A) · Active comparator
- Experimental treatment (Arm B) · Experimental
- Enrollment
- 331
- Primary outcomes
- Event-free survival (EFS)
- Sponsor
- Klinikum Stuttgart with German Federal Ministry of Education and Research, University Hospital Freiburg
- Start
- Jun 28, 2021
- Primary completion
- Jun 2028 (estimated)
- Results posted
- No
- Registry record
- NCT04931368 · updated Mar 18, 2026